Over one year of survival difference between distinct cohorts of glioblastoma patients
Poon, M. T.; Woo, P. Y.; El Helali, A.; Brennan, P. M.
Show abstract
Understanding the differences in outcomes based on study and patient characteristics can inform better research designs and improve the interpretation of translational glioblastoma studies. This study compared the clinical features and median overall survival (mOS) of 2,203 patients from two genomic cohorts (The Cancer Genome Atlas [TCGA] and the Chinese Glioma Genome Atlas [CGGA]) and two consecutive regional cohorts (Hong Kong [HK] and Southeast [SE] Scotland) with histologically confirmed glioblastoma. Differences in clinical characteristics reflected the distinct patient selection criteria for surgery. While the mOS were similar, the mOS of those who completed temozolomide chemoradiotherapy were 35.2 months in SE Scotland, 22.2 in HK, and 14.1 in the TCGA cohort. Survival functions were comparable in the multivariable survival analysis. Our findings highlight how a lack of clinical data impedes the translational value of research. Therefore, there is a need to develop common data elements to derive meaningful conclusions.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study 94%
- The impact of germline variants in DNA repair pathways on survival and temozolomide toxicity in adults with glioma 93%
- A Population Study of Clinical Trial Accrual for Women and Minorities in Neuro-Oncology Following the NIH Revitalization Act 93%
Similar papers in this journal
Similar papers in this journal
- Association of Extent of Resection and Functional Outcomes in Diffuse Low-Grade Glioma: Systematic Review & Meta-Analysis 93%
- Disrupting Akt-Wnt/β-catenin signaling suppresses glioblastoma stem cell growth and tumor progression in immunocompetent mice 92%
- Early Imaging Marker of Progressive Glioblastoma: a window of opportunity 91%
Similar papers in this journal
- Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors 91%
- Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers 90%
- A three gene signature predicts response to selinexor in multiple myeloma 90%
Similar papers in this journal
- Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome 90%
- Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome 89%
- CD8+ T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomas 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.